Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

By sjmartinez • March 7, 2024

Blauvelt A, Armstrong A, Merola JF, Strober B, de Cuyper D, Peterson L, Davies O, Stark JL, Lebwohl M. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials. J Am Acad Dermatol. 2024 Mar 4:S0190-9622(24)00438-9. doi: 10.1016/j.jaad.2024.02.039. Epub ahead of print. PMID: 38447700.

Tags: bimekizumab, Clinical Trial, depression, Dermatology, long-term, mental health, plaque psoriasis, Publications, safety, suicidality, suicide

Inhibition of pyruvate oxidation diminishes melanoma progression

Seyran B, Avila I, Galvan C, Robles G, Murphy C, Christofk H, Lowry WE. Inhibition of pyruvate oxidation diminishes melanoma progression. J Invest Dermatol. 2024[...]

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement

Akiska YM, Mirmirani P, Roseborough I, Mathes E, Bhutani T, Ambrosy A, Aguh C, Bergfeld W, Callender VD, Castelo-Soccio L, Cotsarelis G, Craiglow BG, Desai[...]

Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of Secondary Pathologic Consultation

Zhang R, Yueh K, Anderson M, Bennett RG. Mart-1 During Mohs Micrographic Surgery for Melanoma Excision Results in Decreased Stage Number and Decreased Frequency of[...]